Prothena unveils 2026 share redemption, eyes $105M in clinical milestones
Prothena reported a $244.1 million net loss for 2025 in line with guidance and unveiled a share redemption program planned for 2026. The company is eligible for up to $105 million in clinical milestone payments and plans TDP-43 program presentations in 2026, with Tal-partnered data expected in 2027.
1. Financial performance and share redemption
Prothena closed 2025 with a net loss of $244.1 million, matching prior guidance, and announced plans to initiate a share redemption program in 2026 to optimize its capital structure.
2. Clinical milestone payments and timelines
The company is positioned to earn up to $105 million in clinical milestone payments from partner collaborations in 2026, will present preclinical data on its TDP-43 site program at scientific forums next year, and anticipates data from its Tal-program collaboration with Bristol-Myers Squibb in 2027.
3. Pipeline advancements and partnerships
Prothena highlighted PRX-012’s once-monthly subcutaneous administration enhanced by transferrin receptor technology to boost amyloid clearance, noted imminent phase I readout timing for partnered PRX-019, and emphasized the broad therapeutic potential of its Cyto platform targeting TDP-43 in ALS.